5-Alpha-Reductase Inhibitors and Combination Therapy

被引：17
|
作者：
Fuellhase, Claudius [1 ]
Schneider, Marc P. [2 ]
机构：
[1] Univ Rostock, Dept Urol, Ernst Heydemann Str 6, D-18057 Rostock, Germany
[2] Univ Zurich, Brain Res Inst, Swiss Fed Inst Technol Zurich, Dept Hlth Sci & Technol, Winterthurerstr 190, CH-8057 Zurich, Switzerland
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2016年 / 43卷 / 03期
关键词：
5-Alpha-reductase inhibitors; Finasteride; Dutasteride; Combination drug therapy; Prostatic hyperplasia; Lower urinary tract symptoms; BENIGN PROSTATIC HYPERPLASIA; URINARY-TRACT SYMPTOMS; DOUBLE-BLIND; FINASTERIDE THERAPY; TRANSURETHRAL RESECTION; ENLARGED PROSTATE; 5A-REDUCTASE INHIBITORS; CLINICAL PROGRESSION; SEXUAL FUNCTION; BLOOD-LOSS;
D O I：
10.1016/j.ucl.2016.04.003
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
By inhibiting the conversion from testosterone to dihydrotestosterone 5-Alpha reductase inhibitors (5ARIs) are able to hinder prostatic growth, shrink prostate volumes, and improve BPH-related LUTS. 5ARIs are particularly beneficial for patients with larger prostates (>30-40 mL). Generally the side effects of 5ARI treatment are mild, and according to the FORTA classification 5ARIs are suitable for frail elderly. 5ARI/alpha-blocker (AB) combination therapy showed the best symptomatic outcome and risk reduction for clinical progression. Combining Phosphodieseterase type 5 inhbibitors (PDE5Is) with 5ARIs counteracts the negative androgenic sexual side effects of 5ARIs, and simultaneously combines their synergistic effects on LUTS.
引用
收藏
页码：325 / +
页数：13
相关论文
共 50 条
  • [21] INHIBITORS OF STEROID 5-ALPHA-REDUCTASE WHICH ARE UNCOMPETITIVE VERSUS TESTOSTERONE
    METCALF, BW
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1991, 202 : 8 - MEDI
  • [22] 5-ALPHA-REDUCTASE INHIBITORS IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
    Dai, Charles
    Ganesan, Vishnu
    Zabell, Joseph
    Nyame, Yaw
    Hettel, Daniel
    Almassi, Nima
    Greene, Daniel
    Haywood, Samuel
    Reichard, Chad
    Zampini, Anna
    Crane, Alice
    Arora, Hans
    El-Shafei, Ahmed
    Stein, Robert
    Fareed, Khaled
    Gong, Michael
    Jones, J. Stephen
    Stephenson, Andrew
    Klein, Eric
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E229 - E229
  • [23] Battling Prostate Cancer with 5-Alpha-Reductase Inhibitors: a Pyrrhic Victory?
    Hoffman, Richard M.
    Roberts, Richard G.
    Barry, Michael J.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2011, 26 (07) : 798 - 801
  • [24] 5-ALPHA-REDUCTASE AND POLYCYSTIC OVARIES
    VANSETERS, AP
    MOOLENAAR, AJ
    DERKSEN, J
    [J]. LANCET, 1990, 335 (8700): : 1277 - 1277
  • [25] THE SYNDROME OF 5-ALPHA-REDUCTASE DEFICIENCY
    FRATIANNI, CM
    IMPERATOMCGINLEY, J
    [J]. ENDOCRINOLOGIST, 1994, 4 (04): : 302 - 314
  • [26] FINASTERIDE - A 5-ALPHA-REDUCTASE INHIBITOR
    STEINER, JF
    [J]. CLINICAL PHARMACY, 1993, 12 (01): : 15 - 23
  • [27] Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
    Charles Welliver
    Michael Butcher
    Yogitha Potini
    Kevin T. McVary
    [J]. Current Urology Reports, 2014, 15
  • [28] Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
    Welliver, Charles
    Butcher, Michael
    Potini, Yogitha
    McVary, Kevin T.
    [J]. CURRENT UROLOGY REPORTS, 2014, 15 (10)
  • [29] REGULATION OF DIHYDROTESTOSTERONE IN HUMAN-PROSTATE BY 5-ALPHA-REDUCTASE AND ITS INHIBITORS
    DUNSTANADAMS, E
    BRUCHOVSKY, N
    RENNIE, PS
    GOLDENBERG, L
    MCLOUGHLIN, M
    [J]. CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1985, 8 (03): : A81 - A81
  • [30] A population-based assessment of the cardiovascular safety of 5-alpha-reductase inhibitors
    Ayele, Henok Tadesse
    Reynier, Pauline
    Azoulay, Laurent
    Platt, Robert W.
    Benayoun, Serge
    Filion, Kristian B.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 582 - 583
12345